Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Grants	$ 148,054	$ 239,539
Total revenues	148,054	239,539
Operating costs and expenses:
Research and development	1,700,512	1,725,893
General and administrative	2,651,837	980,589
Total operating costs and expenses	4,352,349	2,706,482
Loss from operations	(4,204,295)	(2,466,943)
Interest and other income (expense)	(200,475)	(184)
Change in fair value of warrant liability	0	19,807
Net loss	(4,404,770)	(2,447,320)
Deemed dividend on Series A-1 preferred stock	0	(9,017,512)
Deemed dividend on Series A-1 warrant	0	(179,411)
Deemed dividend on Series B preferred stock	0	(8,655,998)
Accretion of preferred stock dividends	0	(93,234)
Net loss allocable to common stockholders	$ (4,404,770)	$ (20,393,475)
Basic and diluted net loss per share	$ (0.15)	$ (6.25)
Shares used to calculate basic and diluted net loss per share	29,208,186	3,262,599